A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682 and MK-8408 When Coadministered to Subjects With Moderate and Severe Hepatic Insufficiency
Phase of Trial: Phase I
Latest Information Update: 31 May 2017
At a glance
- Drugs Ruzasvir (Primary) ; Uprifosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 19 Jan 2017 Status changed from recruiting to completed.
- 29 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Feb 2017.
- 29 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Feb 2017.